In addition, a large proportion of patients biochemically controlled (insulin-like growth factor I (IGF1) ≤ 1.3 × upper limit of normal (ULN)) on injectable SRLs report persistent acromegaly symptoms that interfere with their daily lives (11). The gene discussed is IGF1; the disease is acromegaly.